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Background: Since 2006 antiretroviral therapy is widely avail-
able in most regions of Russia. According to Russian national
HIV/AIDS clinical guidelines combination of zidovudine, lamivu-
dine and efavienz (AZT/3TC+EFV respectively) is the only preferred
regimen for antiretroviral-naive adults and in case of resistance,
EFV could be changed to etravirine. Some patients demonstrate
virologiv failure on ﬁrst-line regimen. In themajority of these cases
virologic failure appears after undetectable viral load has been
achieved.
Methods & Materials: We investigated spectrum and preva-
lence of certain NNRTI-associated mutations in patients with
virologic failure on the ﬁrst-line combination of AZT/3TC+EFV in
Yekaterinburg, Russia. A total of 60 Russian subjects who have
developed virologic failure after one year of successful ARV ther-
apy (with undetectable viral load) consisting of AZT/3TC+EFV were
enrolled in this cross-sectional study based on data obtained from
July 2011 to December 2012. HIV-1 genotypes from these patients
were analysed for NNRTI mutations.
Results: All patients have shown NNRTI-associated mutations.
65% of patients developed only one mutation - K103N which is
associated with resistance to efavirenz. 35% of patients developed
etravirine-associatedmutations:5%ofpatientsdeveloped3NNRTI-
associated mutations: Y181C + G190S + K101E, which corresponds
to thehighest level of resistance to etravirine. 20%of patients devel-
oped either single Y181C (5 patients), or G190S+K101E (6 patients),
or single mutation Y181 (1 patient), or single L100I (1 patient),
which means possible resistance to etravirine. We have also iden-
tiﬁed single G190S in 2 patients, single K101E in 2 patients, single
A98G in one patient, and single V179D in one patient.
Conclusion: Our results have shown that in patients with viro-
logic failure on AZT/3TC+EFV, K103N (which makes further use of
efavirenz impossible) is the most common mutation. Also in 35% of
cases, etravirine-associated mutations have been found. It means
that in some patients further treatment with NNRTI is impossible.
Thus genotyping should be performed in all patients with virologic
failure on ﬁrst-line regimen in Russia to guide future selection of
antiretroviral regimens.
http://dx.doi.org/10.1016/j.ijid.2014.03.677
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HIV–malaria coinfection: Anti-malaria therapy
in people living with HIV/AIDS in Owerri, Nigeria
C.N. Ukaga
Imo State University Owerri, Owerri, Nigeria
Background: Studies show that HIV and malaria infections fuel
each other. The need to identify the most effective anti-malaria
drug for PLWHA in malaria endemic communities was the main
focus for this study.
Methods & Materials: This was a hospital based study using
the Heart to Heart clinic of the Imo Specialist Hospital as the
study site. Ethical clearance was obtained from all relevant author-
ities. Study participants were both HIV+ and HIV− volunteers.
Study volunteers were placed in six respective groups of dif-
ferent commonly available anti-malaria combination therapies
thus: Coartem (Artemether + Lumefantrine), Blofast (Artesunate
+Meﬂoquin), Waipa (Dihydroartemisin + Piperequnie Phosphate),
Winthrop (Artesunate +Amodiaquine),Maltarka (Artesunate + Sul-
fadoxine + Pyrimethamine) and non ACT Laridox (Sulfadoxine +
Pyrimethamine). Malaria parasitemia, CD4 cells count, Haemato-
logical parameters (haemoglobin level, packed cell volume, total
white blood cells count, neutrophils and lymphocyte cells count as
well as erythrocyte sedimentation rate [ESR]) were assessed using
routine techniques pre and 2 weeks post treatment with respec-
tive anti-malaria therapy from 5mls venous blood taken from each
volunteer.
Results: The study population was 473 volunteers made up
of HIV+ and HIV−. Coartem in PLWHA reduced the malaria para-
sitemia signiﬁcantly, increased the CD4 cell counts, with a marked
reduction of ESR. Blofast treatment in PLWHA resulted in increased
malaria parasitemia, decreased CD4 cells, increased lymphocytes
and ESR, as well as decreased neutrophils. Waipa treatment in
PLWHA resulted in a decreased malaria parasitemia, decreased
CD4 cells, increased neutrophils and ESR as well as decreased
lymphocytes. Winthrop in PLWHA showed only a very slight
decrease in malaria parasitemia, decreased CD4 cells, a marked
reduction in both ESR and lymphocytes cells as well as a sharp
increase in the neutrophils. Maltarka in PLWHA decreased malaria
parasitemia, with a marked increase in CD4 cells, increased neu-
trophils and ESR, and decreased lymphocytes cell count. Laridox in
PLWHA, increasedmalaria parasitemia, decreased CD4 cells, exhib-
ited reduction in both ESR and lymphocytes cell count with a sharp
increase in the neutrophils.
Conclusion: Findings from this study indicate that Coartem
(Arthemeter + Lumefantrin) appears to be most effective ACT for
PLWHA. Other implications are discussed.
http://dx.doi.org/10.1016/j.ijid.2014.03.678
